Elevance Health's Q2 2026 Earnings and Growth Prospects

Elevance Health's second-quarter earnings for 2026 are expected. The company's future earnings growth prospects will depend on various factors, including Carelon's performance.

ELV (Elevance Health), the managed-care insurer formerly known as Anthem, is preparing to report second-quarter 2026 earnings, with investors focused on how the company is navigating cost trends across its health-benefits and services businesses.

A central question is the contribution from Carelon, Elevance's fast-growing health-services arm that spans pharmacy, care delivery and data analytics. Management has positioned Carelon as a key growth engine, and its performance is expected to be a swing factor for both quarterly results and full-year guidance.

Beyond Carelon, managed-care investors typically watch the medical-loss ratio, membership trends and any commentary on utilization, which has been a sector-wide concern. A beat with reaffirmed or raised guidance could rebuild confidence, while signs of rising medical costs or Carelon softness could weigh on the shares. The report will offer a fresh read on how Elevance is balancing growth against cost pressure.